Related Experiment Videos
Clinical outcome of ulcerative colitis in children
J S Hyams1, P Davis, K Grancher
1Department of Pediatrics, Connecticut Children's Medical Center, Hartford, USA.
Insights
Pediatric ulcerative colitis (UC) patients often achieve remission within 6 months. Initial disease severity is a key predictor of colectomy risk within five years, suggesting tailored therapies for moderate to severe cases.
Area of Science:
- Pediatric Gastroenterology
- Inflammatory Bowel Disease Research
- Clinical Outcomes
Background:
- Ulcerative colitis (UC) is a chronic inflammatory bowel disease affecting children.
- Understanding treatment response and long-term outcomes in pediatric UC is crucial for effective management.
Purpose of the Study:
- To evaluate the effectiveness of current medical therapies for pediatric ulcerative colitis.
- To identify predictors of colectomy in children diagnosed with UC.
Main Methods:
- Retrospective chart review of 171 pediatric patients with ulcerative colitis.
- Analysis of disease severity at presentation, treatment response, and colectomy rates over a mean follow-up of 5.1 years.
Main Results:
- Remission was achieved by 90% of mild and 81% of moderate/severe UC cases within 6 months.
- Approximately 50% of patients remained symptom-free annually post-initial treatment.
- Colectomy risk at 5 years was 9% for mild disease vs. 26% for moderate/severe disease (p <0.03).
Conclusions:
- Most pediatric ulcerative colitis patients achieve initial remission.
- Initial disease severity significantly impacts the long-term risk of colectomy.
- More aggressive initial treatment strategies may benefit children with moderate to severe UC.
Objectives:
To characterize the response to current medical therapies in children with ulcerative colitis, and to identify those factors that may predict the need for colectomy.
Design:
Retrospective chart review at two large pediatric inflammatory bowel disease centers.
Results:
We identified 171 subjects ranging in age from 1.5 to 17.7 years at diagnosis (mean 11.2 years). Mean follow-up was 5.1 years. Of these subjects, 43% had mild disease at presentation and 57% had disease that was classified as moderate or severe. After treatment 90% of the former group and 81% of the latter group had resolution of symptoms by 6 months. During any subsequent yearly follow-up interval, approximately 55% of the entire study population was symptom free, 38% had chronic intermittent symptoms, and 7% had continuous symptoms. A significantly lower risk of colectomy was noted for those with initially mild disease compared with those with moderate/severe disease. At 1-year the risk of colectomy was 1% among those with mild disease versus 8% with moderate/severe disease; at 5 years, the risk of colectomy was 9% in the mild disease group versus 26% in the moderate/severe disease group (p <0.03).
Conclusions:
In the majority of pediatric subjects with ulcerative colitis remission is achieved in the first 6 months after therapy; thereafter disease is inactive in about 50% of patients during any given year of follow-up. Severity of disease at presentation is a significant risk factor for colectomy during the first 5 years of follow-up. Future management protocols with more aggressive initial therapy may be warranted in children with moderate/severe disease.